Patient info Open main menu

Weleda Relaxing Oral Drops – Summary of Product Characteristics (SmPC) for healthcare professionals

Last updated: · Text from the MHRA, as of · About this document

Medicine status: General sale (GSL) Details

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet: how to take, side effects, pregnancy and breast-feeding.

Contains active substances:

Summary of Product Characteristics (SmPC) - Weleda Relaxing oral drops

1 NAME OF THE MEDICINAL PRODUCT

Weleda Relaxing Oral Drops

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1ml of oral liquid contains:

Avena sativa mother tincture 0.25ml [equivalent to 121mg fresh Avena sativa herb].

Extraction solvent: Ethanol 62% w/w

Humulus lupulus mother tincture 0.04ml [equivalent to 3mg Hops Strobile]. Extraction solvent: Ethanol 86% w/w

Passiflora incarnata mother tincture 0.075ml [equivalent to 23mg fresh Passion Flower herb].

Extraction solvent: Ethanol 86% w/w

Valeriana officinalis mother tincture 0.3ml [equivalent to 26mg Valerian root]. Extraction solvent: Ethanol 43% w/w

Coffea tosta 60X 0.15ml

1 ml is equivalent to 34 drops.

1 ml of oral liquid contains approximately 357 mg of ethanol (alcohol) equivalent to 9.5 ml beer or 3.9 ml wine.

For full list of excipients see Section 6.1.

3 PHARMACEUTICAL FORM

Oral drops, solution

Clear, yellow-brown liquid

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

A homeopathic medicinal product used within the homeopathic tradition for the temporary relief of mild symptoms associated with stress and to aid sleep.

4.2 Posology and method of administration

Adults and the elderly:

For the temporary relief of mild stress symptoms: 0.75ml – 1.0ml in a small glass of water, three times a day.

To aid sleep: 1.0 ml – 2.0ml in a small glass of water, half an hour before retiring to bed.

Maximum daily dose is 5.0 ml.

Not recommended for use in children and adolescents under 18 years of age (see Section 4.4 ‘Special warnings and precautions for use’).

How to use the dropper:

  • Unscrew the cap by pushing the cap down and twisting in an anti-clockwise direction
  • Hold the bottle upright and place the dropper inside the bottle
  • Squeeze the bulb to draw the amount of solution required into the dropper to either the 0.75ml or 1ml marking on the side of the dropper as appropriate (see the recommended dose section for the correct dose)
  • If too much solution has been drawn up into the dropper, gently squeeze the bulb to release the solution back into the bottle until the correct dose has been measured
  • If too little solution has been drawn up, replace the dropper into the bottle and gently squeeze to draw up more solution
  • After use, screw the dropper back onto the bottle.

Method of administration

For oral, short term use only.

Duration of use

If the symptoms worsen, or persist after one week, a doctor or qualified healthcare practitioner should be consulted.

4.3 Contraindications

Hypersensitivity to the active substances or any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Do not exceed the stated dose.

If the symptoms worsen, or persist after one week, a doctor or qualified healthcare practitioner should be consulted.

Not to be used repeatedly without consulting a doctor or qualified healthcare practitioner.

The use of this product in children and adolescents under 18 years of age is not recommended because data are not sufficient and medical advice should be sought.

The amount of alcohol in 1ml is 357 mg. The maximum recommended dose of this medicine (5.0 ml) will increase the concentration of alcohol in the body by approximately 380 mg/L. This is equivalent to drinking 47.5ml of beer or 19.5ml of wine.

The small amount of alcohol in this medicine will not have any noticeable effects.

4.5 Interaction with other medicinal products and other forms of interaction

Contains alcohol and should be avoided in patients taking other medicines known to interact with alcohol (e.g. metronidazole, disulfiram).

Additive effects with hypnotics and other sedatives cannot be excluded and therefore co-medication is not recommended as a general precaution.

The effects of this product may be potentiated by alcohol. Excessive concomitant consumption of alcohol should therefore be avoided.

4.6 Fertility, pregnancy and lactation

The safety of this product during pregnancy and lactation has not been established, therefore in the absence of sufficient data the use of this product during pregnancy and lactation is not recommended.

Studies on the effects of fertility have not been performed.

4.7 Effects on ability to drive and use machines

May impair the ability to drive or use machines. Affected patients should not drive or use machines.

This product contains alcohol (see Section 4.4).

4.8 Undesirable effects

The following side effects have been reported with Valerian root preparations: Gastrointestinal symptoms such as nausea, vomiting, abdominal cramps and diarrhoea may occur. Dizziness, headaches and nightmares or vivid dreams may also occur. The frequency is not known.

One case of hypersensitivity (vasculitis) and one case of nausea and tachycardia have been reported after ingestion of much higher levels of Passion Flower herb preparations.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play of Apple App Store.

4.9 Overdose

No case of overdose has been reported. Overdose of this product may result in alcohol intoxication. The amount in a full bottle [17.86g in 50ml], is equivalent to 475ml of beer or 195ml of wine and may result in intoxication and should be treated accordingly.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Not required

5.2 Pharmacokinetic properties

Not required

5.3 Preclinical safety data

Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Ethanol

Purified water

6.2 Incompatibilities

Not applicable

6.3 Shelf life

4 years

6.4 Special precautions for storage

Do not store above 25oC.

Store in the original container.

6.5 Nature and contents of container

Violet glass bottle with a TPE bulb and graduated glass dropper incorporating a HDPE child resistant and tamper evident cap.

25ml, 50ml and 100ml pack sizes available. Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements

7 MARKETING AUTHORISATION HOLDER

Weleda UK Ltd

Etiquette Park

Ilkeston

Derbyshire

DE7 8FU

UK

8 MARKETING AUTHORISATION NUMBER(S)

NR 00298/0298

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

04/05/2021

10 DATE OF REVISION OF THE TEXT

11/02/2026

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: NR002980298

Last revision stated in the text: 11 February 2026 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Weleda Relaxing oral drops

Prescription needed? No, general sale list medicine (GSL) – also sold outside pharmacies
Active substances Avena, Coffea tosta, Passion flower extract, Valerian extract, Hops extract, Ethanol
Pharmaceutical form Homeopathic drops
Clear, yellow-brown liquid
How is it taken Oral
Excipients Ethanol, Purified water
Pack sizes 50 ml
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 4 years
Storage Do not store above 25°C.
Store in the original container.
Marketing authorisation NR 00298/0298 (first authorised 4 May 2021)
Marketing authorisation holder Weleda UK Ltd
Codes GTIN 5013455260399 · BNF 19020300

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.